Alnylam Pharmaceuticals
ALNY
#378
Rank
โ‚น5.437 T
Marketcap
โ‚น41,156
Share price
-1.55%
Change (1 day)
93.00%
Change (1 year)
Alnylam Pharmaceuticals Inc. is a biopharmaceutical company focused on the R&D and commercialization of RNA interference (RNAi) therapeutics for genetically defined diseases.

EPS for Alnylam Pharmaceuticals (ALNY)

EPS in 2025 (TTM): โ‚น15.44

According to Alnylam Pharmaceuticals 's latest financial reports the company's current EPS (TTM) is โ‚น8.09. In 2023 the company made an earnings per share (EPS) of -โ‚น317.12 an increase over its 2022 EPS that were of -โ‚น834.58.

EPS history for Alnylam Pharmaceuticals from 2012 to 2025

Annual EPS

Year EPS Change
2025 (TTM)โ‚น15.44
2023-โ‚น317.12-62%
2022-โ‚น834.5829.03%
2021-โ‚น646.82-3.36%
2020-โ‚น669.28-8.48%
2019-โ‚น731.277.67%
2018-โ‚น679.1639.74%
2017-โ‚น486.0112.94%
2016-โ‚น430.3238.84%
2015-โ‚น309.94-32.88%
2014-โ‚น461.76259.44%
2013-โ‚น128.47-31.25%
2012-โ‚น186.86

EPS for similar companies or competitors

Company EPS EPS differencediff. Country
Arrowhead Pharmaceuticals
ARWR
-โ‚น112.30-1,488.89%๐Ÿ‡บ๐Ÿ‡ธ USA
Regeneron Pharmaceuticals
REGN
โ‚น3,902 48,166.67%๐Ÿ‡บ๐Ÿ‡ธ USA
Sarepta Therapeutics
SRPT
-โ‚น246.15-3,144.44%๐Ÿ‡บ๐Ÿ‡ธ USA
OPKO Health
OPK
-โ‚น21.56-366.67%๐Ÿ‡บ๐Ÿ‡ธ USA
Regulus Therapeutics
RGLS
-โ‚น65.58-911.11%๐Ÿ‡บ๐Ÿ‡ธ USA
Novartis
NVS
โ‚น661.20 8,077.78%๐Ÿ‡จ๐Ÿ‡ญ Switzerland
Sanofi
SNY
โ‚น332.91 4,017.43%๐Ÿ‡ซ๐Ÿ‡ท France
Teva Pharmaceutical Industries
TEVA
โ‚น56.60 600.00%๐Ÿ‡ฎ๐Ÿ‡ฑ Israel